Breaking News Instant updates and real-time market news.

COO

Cooper Companies

$276.94

2.04 (0.74%)

05:19
12/07/18
12/07
05:19
12/07/18
05:19

Cooper fundamentals strong despite currency headwinds, says Piper Jaffray

Piper Jaffray analyst Matt O'Brien raised his price target for Cooper Companies to $300 from $280 following the company's "mixed" Q4 results. Revenue beat expectations but earnings came in light due to currency and some transitory product costs, O'Brien tells investors in a post-earnings research. Further, the company's guidance for 2019 was below the Street largely due to a negative currency outlook, adds the analyst. However, O'Brien believes the fundamentals of Cooper's business remain strong. He points out that currency related selloffs typically represent good buying opportunities and keeps an Overweight rating on Cooper Companies.

  • 12

    Dec

COO Cooper Companies
$276.94

2.04 (0.74%)

08/31/18
KEYB
08/31/18
NO CHANGE
Target $298
KEYB
Overweight
Cooper Companies earnings pullback a buying opportunity, says KeyBanc
KeyBanc analyst Matthew Mishan views the post-earnings pulback in shares of Cooper Companies as an opportunity. Bigger picture, the company's revenue growth momentum appears sustainable, Mishan tells investors in a research note. Cooper's sales beat with revenue growth inflecting sequentially, ahd the pull-though to earnings was understandably offset by current and elevated investment, the analyst contends. He reiterates an Overweight rating on Cooper Companies with a $298 price target.
08/31/18
JEFF
08/31/18
NO CHANGE
Target $295
JEFF
Buy
Cooper Companies beat in Q3 when factoring in currency, says Jefferies
Jefferies analyst Anthony Petrone says that despite optically posting a 7c earnings miss in fiscal Q3, Cooper Companies' underlying performance was ahead when currency is factored. U.S. growth increased to 8% on share gains and strength in dailies offsetting Biofinity supply constraints, Petrone tells investors in a post-earnings research note titled "Still a Share Gain Story That is Now More Offensive; PT to $295." The analyst still sees a path for steady 10%-plus earnings growth and upped his price target for the shares to $295 from $285. Petrone keeps a Buy rating on Cooper Companies.
10/16/18
PIPR
10/16/18
NO CHANGE
PIPR
Piper Jaffray discusses derivatives from J&J's Q3 results
Piper Jaffray analyst Matt O'Brien notes that Johnson & Johnson's (JNJ) global Medical Devices segment grew 1.7% organically in Q3, with sales of $6.6B falling $50M short of the consensus. The large joint segment continues to look relatively stable, with low-single-digit pricing pressures as expected, O'Brien tells investors in a research note. The analyst suspects Stryker (SYK) will continue to take share away from J&J and Zimmer Biomet (ZBH) in Q3. J&J's Spine segment was flat off of easy comps and after normalizing the Codman divestiture, the analyst adds. He continues to view J&J as a "share donor" to the pure-play spine names Globus Medical (GMED), NuVasive (NUVA) and SeaSpine (SPNE), with Globus' robot "continuing to provide share taking opportunities." Within Contact Lenses, J&J faced tough comps but reported a solid quarter in both the domestic and international markets, O'Brien says. He continues to see a "healthy" lens end market and one that is shifting to daily lenses from reusable, which he views as positive for Cooper Companies (COO). Further, the analyst notes that Diabetes continues to decelerate for J&J at a negative 20% clip given the Animas exit, which he thinks continues to be a positive for the pump names Insulet (PODD) and Tandem Diabetes (TNDM).
11/20/18
PIPR
11/20/18
NO CHANGE
Target $280
PIPR
Overweight
Cooper fundamentals strong despite dollar headwind, says Piper Jaffray
After speaking with a mid-sized contact lens distributor, Piper Jaffray analyst Matt O'Brien believes Cooper Companies' fundamentals remain "quite strong." Overall, the market for contacts remains healthy and it appears the dropout rate for lenses is falling slightly, which should help the category, O'Brien tells investors in a research note. The analyst, however, believes the strengthening U.S. dollar will again hurt Cooper's revenue and earnings outlook for the business. He lowered his estimates for the company but keeps an Overweight rating on the name with a $280 price target. O'Brien thinks Cooper remains one of the more compelling names in Medtech.

TODAY'S FREE FLY STORIES

DERM

Dermira

$14.13

1.52 (12.05%)

19:40
03/19/19
03/19
19:40
03/19/19
19:40
Syndicate
Dermira 9.8M share Secondary priced at $13.25 per share »

Citi, Cowen, Cantor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

NVRO

Nevro

$44.76

0.37 (0.83%)

19:38
03/19/19
03/19
19:38
03/19/19
19:38
Upgrade
Nevro rating change  »

Nevro upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

TORC

ResTORbio

$7.16

-1.81 (-20.18%)

19:34
03/19/19
03/19
19:34
03/19/19
19:34
Syndicate
ResTORbio 7.2M share Secondary priced at $6.95 »

BofA/Merrill, SVB Leerink…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

NVRO

Nevro

$44.76

0.37 (0.83%)

19:33
03/19/19
03/19
19:33
03/19/19
19:33
Upgrade
Nevro rating change  »

Nevro upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

PFE

Pfizer

$42.32

0.51 (1.22%)

, MKGAY

Merck KGaA

$0.00

(0.00%)

19:17
03/19/19
03/19
19:17
03/19/19
19:17
Hot Stocks
Pfizer, Merck KGaA discontinue Phase III JAVELIN Ovarian PARP study »

Merck KGaA (MKGAY) and…

PFE

Pfizer

$42.32

0.51 (1.22%)

MKGAY

Merck KGaA

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 30

    Apr

  • 18

    May

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

, GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

19:11
03/19/19
03/19
19:11
03/19/19
19:11
Hot Stocks
Google outlines changes to Android mobile options, ad formats in Europe »

Google said in a blog…

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

, GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

19:08
03/19/19
03/19
19:08
03/19/19
19:08
Periodicals
Google offers Android, product ad concessions for Europe, WSJ says »

Google intends to ask all…

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

SMAR

Smartsheet

$43.51

-0.16 (-0.37%)

, SCS

Steelcase

$17.49

-0.115 (-0.65%)

19:06
03/19/19
03/19
19:06
03/19/19
19:06
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

SMAR

Smartsheet

$43.51

-0.16 (-0.37%)

SCS

Steelcase

$17.49

-0.115 (-0.65%)

AUPH

Aurinia Pharmaceuticals

$6.40

0.13 (2.07%)

NVRO

Nevro

$44.76

0.37 (0.83%)

SAGE

Sage Therapeutics

$156.08

-0.89 (-0.57%)

TME

Tencent Music

$18.65

-0.48 (-2.51%)

WPRT

Westport

$1.50

(0.00%)

AIR

AAR Corp.

$35.10

(0.00%)

FDX

FedEx

$181.50

-0.92 (-0.50%)

FNV

Franco-Nevada

$75.64

0.035 (0.05%)

PRNB

Principia Biopharma

$36.88

0.48 (1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 21

    Mar

  • 01

    Apr

  • 02

    Apr

  • 05

    Apr

  • 14

    May

  • 28

    May

  • 24

    Jun

  • 26

    Jun

LGIH

LGI Homes

$54.89

-2.27 (-3.97%)

19:02
03/19/19
03/19
19:02
03/19/19
19:02
Hot Stocks
LGI Homes announces new community in Las Vegas »

LGI Homes, Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$156.08

-0.89 (-0.57%)

19:01
03/19/19
03/19
19:01
03/19/19
19:01
Hot Stocks
Sage says Zulresso approval represents 'game-changing approach' to PPD »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

QTRX

Quanterix

$24.59

-0.01 (-0.04%)

18:55
03/19/19
03/19
18:55
03/19/19
18:55
Syndicate
Breaking Syndicate news story on Quanterix »

Quanterix files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIHS

Senmiao Technology

$4.71

-0.275 (-5.52%)

18:55
03/19/19
03/19
18:55
03/19/19
18:55
Syndicate
Breaking Syndicate news story on Senmiao Technology »

Senmiao Technology files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$23.31

-0.23 (-0.98%)

18:54
03/19/19
03/19
18:54
03/19/19
18:54
Syndicate
Breaking Syndicate news story on Invitation Homes »

Invitation Homes files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

PULM

Pulmatrix

$1.70

-0.09 (-5.03%)

18:53
03/19/19
03/19
18:53
03/19/19
18:53
Syndicate
Breaking Syndicate news story on Pulmatrix »

Pulmatrix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

SIEN

Sientra

$8.81

-0.4 (-4.34%)

18:51
03/19/19
03/19
18:51
03/19/19
18:51
Recommendations
Sientra analyst commentary at Wells Fargo »

Sientra implied costs to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$23.31

-0.23 (-0.98%)

18:50
03/19/19
03/19
18:50
03/19/19
18:50
Syndicate
Breaking Syndicate news story on Invitation Homes »

Invitation Homes files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

FDX

FedEx

$181.50

-0.92 (-0.50%)

18:45
03/19/19
03/19
18:45
03/19/19
18:45
Hot Stocks
FedEx CEO: Domestic business is pretty good »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

LYFT

Lyft

$0.00

(0.00%)

18:41
03/19/19
03/19
18:41
03/19/19
18:41
Periodicals
Lyft IPO oversubscribed so far, Reuters reports »

Lyft's IPO is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

NSTG

NanoString

$24.27

-3.03 (-11.10%)

18:37
03/19/19
03/19
18:37
03/19/19
18:37
Syndicate
NanoString 4.5M share Secondary priced at $23.00 »

JPMorgan, UBS and Cowen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

GLD

SPDR Gold Shares

$123.39

0.35 (0.28%)

18:37
03/19/19
03/19
18:37
03/19/19
18:37
Hot Stocks
Breaking Hot Stocks news story on SPDR Gold Shares »

SPDR Gold Shares holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCLH

Norwegian Cruise Line

$56.11

-0.03 (-0.05%)

18:33
03/19/19
03/19
18:33
03/19/19
18:33
Hot Stocks
Norwegian Cruise Line CEO: There is no recession »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

NTNX

Nutanix

$38.78

0.425 (1.11%)

18:23
03/19/19
03/19
18:23
03/19/19
18:23
Hot Stocks
Nutanix CEO: Our churn is really small »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

  • 04

    Apr

  • 09

    Jul

FDX

FedEx

$181.50

-0.92 (-0.50%)

18:20
03/19/19
03/19
18:20
03/19/19
18:20
Earnings
FedEx says started FY19 expecting revenue to rise $6B, but will see $4.5B »

This implies FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

SAGE

Sage Therapeutics

$156.08

-0.89 (-0.57%)

18:04
03/19/19
03/19
18:04
03/19/19
18:04
Hot Stocks
FDA approves Sage Therapeutics' Zulresso in PPD treatment »

The FDA approved Zulresso…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

FDX

FedEx

$181.50

-0.92 (-0.50%)

18:02
03/19/19
03/19
18:02
03/19/19
18:02
Hot Stocks
FedEx says reviewing capital expense plan for FY20 »

Sees FY19 effective tax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.